The observed counts of the four APC-mutated groups (A, AK, AP and AKP) show that APC usually co-occurs with either KRAS or TP53 mutations, or both (Supplementary Table 3); of 312 such tumours, only 43 (14%) are in Group A (APC only), suggesting that APC mutations need to partner with one or more additional driver mutations to advance to CRCs. The gene discussed is TP53; the disease is neoplasm.